SCHEMBL11976532

SCHEMBL11976532

O=C(O)Cc1ccc2ccn(Cc3cccc(-c4ccccc4)c3)c2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.53
HDAC8 Q9BY41 2/20 0.46
BRD4 O60885 1/20 0.46
PPARG P37231 1/20 0.46
PTGS2 P35354 1/20 0.45
ABCC4 O15439 1/20 0.45
LMNA P02545 1/20 0.45
GAA P10253 1/20 0.45
TSHR P16473 1/20 0.45
PTGS1 P23219 1/20 0.45
HTT P42858 1/20 0.45
BACE1 P56817 2/20 0.45
PLA2G10 O15496 1/20 0.44
PLA2G2A P14555 1/20 0.44
APP P05067 1/20 0.44
SNCA P37840 1/20 0.44
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
GLO1 Q04760 1/20 0.43
HDAC1 Q13547 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11976844 0.91 HTR6 (0.56) HTR6HDAC8BRD4ABCC4LMNA
SCHEMBL8387304 0.90 HDAC8 (0.55) HTR6HDAC8BRD4BACE1APP
SCHEMBL11977343 0.86 HDAC8 (0.52) HTR6HDAC8PTGS1BACE1APP
SCHEMBL11975783 0.85 EPHX2 (0.47) HTR6HDAC8PPARGBACE1APP
SCHEMBL11977062 0.85 HDAC8 (0.49) HDAC8BRD4PTGS1BACE1POLB
SCHEMBL11976525 0.85 LMNA (0.54) HTR6HDAC8LMNABACE1APP
SCHEMBL11976537 0.84 FFAR1 (0.51) HTR6HDAC8LMNAGAABACE1
SCHEMBL11976841 0.82 MAPT (0.48) HDAC8LMNA
SCHEMBL11977068 0.82 HDAC8 (0.60) HDAC8LMNAPTGS1HDAC1HDAC2
SCHEMBL11976843 0.81 SLC22A12 (0.45) HTR6HDAC8PPARGABCC4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9359350-B2 Ring-fused compound SATO PHARMACEUTICAL CO., LTD. (JP) 2016-06-07 US disclosed
US-9359350-B2 Ring-fused compound SATO PHARMACEUTICAL CO., LTD. (JP) 2016-06-07 US disclosed
US-20150203490-A1 RING-FUSED COMPOUND SATO PHARMACEUTICAL CO., LTD. (JP) 2015-07-23 US disclosed
US-20150203490-A1 RING-FUSED COMPOUND SATO PHARMACEUTICAL CO., LTD. (JP) 2015-07-23 US disclosed
US-8987473-B2 Ring-fused compound SATO PHARMACEUTICAL CO., LTD. (JP) 2015-03-24 US disclosed
US-8987473-B2 Ring-fused compound SATO PHARMACEUTICAL CO., LTD. (JP) 2015-03-24 US disclosed
WO-2012102405-A1 RING-FUSED COMPOUND 佐藤製薬株式会社 (JP) 2012-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203490-A1 RING-FUSED COMPOUND URB2, RCOR1, RCC2 HTR6 4126/4885HDAC8 2042/4885BRD4 1694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.